This product is for research use only, not for human use. We do not sell to patients.
Size | Price | Stock |
---|---|---|
250mg | $1250 | Check With Us |
500mg | $1850 | Check With Us |
1g | $2775 | Check With Us |
Cat #: V0913 CAS #: 1186486-62-3 Purity ≥ 98%
Description: Evacetrapib (also known as LY-2484595; LY2484595), a benzazepine compound, is a potent and selective inhibitor of CETP (Cholesteryl ester transfer protein) with the potential to lower cholesterol levels and to prevent cardiovascular diseases.
Publications Citing InvivoChem Products
Product Promise
- Physicochemical and Storage Information
- Protocol
- Related Biological Data
- Stock Solution Preparation
- Quality Control Documentation
Molecular Weight (MW) | 638.65 |
---|---|
Molecular Formula | C31H36F6N6O2 |
CAS No. | 1186486-62-3 |
Storage | -20℃ for 3 years in powder formr |
-80℃ for 2 years in solvent | |
Solubility In Vitro | DMSO: 12.8 mg/mL (20.0 mM)r |
Water: <1 mg/mLr | |
Ethanol: 12.8 mg/mL (20.0 mM) | |
Solubility In Vivo | 15% Captisol: 30 mg/mL |
SMILES Code | O=C([C@H]1CC[C@H](CN2C3=C(C)C=C(C)C=C3[C@@H](N(CC4=CC(C(F)(F)F)=CC(C(F)(F)F)=C4)C5=NN(C)N=N5)CCC2)CC1)O |
Synonyms | Evacetrapib; LY 2484595; LY2484595; LY-2484595 |
Protocol | In Vitro | Evacetrapib is a novel benzazepine-based CETP inhibitor. In the buffer CETP assay, the absolute potency of the compound is 5.5 nM. In the human plasma CETP assay, the CETP concentration is about 2 μg/mL (25 nM) and the 36 nM IC50 value again indicates that Evacetrapib is a potent CETP inhibitor against either the recombinant protein or CETP from human plasma. Evacetrapib is apparently much more potent than Dalcetrapib. |
---|---|---|
In Vivo | In double transgenic mice expressing human CETP and apoAI, Evacetrapib exhibits an ex vivo CETP inhibition ED50 of less than 5 mg/kg at 8 h post oral dose and significantly elevated HDL cholesterol. Importantly, no blood pressure elevation is observed in rats dosed with Evacetrapib at high exposure multiples compared with the positive control, torcetrapib. Evacetrapib administered orally at 30 mg/kg results in 98.4%, 98.6%, and 18.4% inhibition of CETP activity at 4, 8 and 24 h post dose respectively. Evacetrapib dosed orally at 30 mg/kg resulted in 129.7% increase in HDL-C 8 h after oral administration. |
Solvent volume to be added | Mass (the weight of a compound) | |||
---|---|---|---|---|
Mother liquor concentration | 1mg | 5mg | 10mg | 20mg |
1mM | 1.5658 mL | 7.8290 mL | 15.6580 mL | 31.3161 mL |
5mM | 0.3132 mL | 1.5658 mL | 3.1316 mL | 6.2632 mL |
10mM | 0.1566 mL | 0.7829 mL | 1.5658 mL | 3.1316 mL |
20mM | 0.0783 mL | 0.3915 mL | 0.7829 mL | 1.5658 mL |
This equation is commonly abbreviated as: C1 V1 = C2 V2
- (1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
- (2) Be sure to add the solvent(s) in order.